OPN-exon-4 immunohistochemistry was only marginally discriminating for cancer in the same breast, but may have a substantially reduced fraction of low-risk scores when cancer is later experienced in the contralateral breast (Fig. 4, for various cutoffs, see Additional file 1: Figure S1). This evidence concerns the gene SPP1 and cancer.